- Home
- PTIX vs QNRX Comparison
PTIX vs QNRX Comparison
Compare PTIX & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTIX
- QNRX
- Stock Information
- Founded
- PTIX 1994
- QNRX 2018
- Country
- PTIX United States
- QNRX United States
- Employees
- PTIX N/A
- QNRX N/A
- Industry
- PTIX Biotechnology: Pharmaceutical Preparations
- QNRX Medical/Dental Instruments
- Sector
- PTIX Health Care
- QNRX Health Care
- Exchange
- PTIX Nasdaq
- QNRX Nasdaq
- Market Cap
- PTIX 3.3M
- QNRX 3.3M
- IPO Year
- PTIX 2016
- QNRX N/A
- Fundamental
- Price
- PTIX $3.83
- QNRX $9.60
- Analyst Decision
- PTIX
- QNRX
- Analyst Count
- PTIX 0
- QNRX 0
- Target Price
- PTIX N/A
- QNRX N/A
- AVG Volume (30 Days)
- PTIX 210.6K
- QNRX 12.9K
- Earning Date
- PTIX 08-13-2025
- QNRX 08-07-2025
- Dividend Yield
- PTIX N/A
- QNRX N/A
- EPS Growth
- PTIX N/A
- QNRX N/A
- EPS
- PTIX N/A
- QNRX N/A
- Revenue
- PTIX N/A
- QNRX N/A
- Revenue This Year
- PTIX N/A
- QNRX N/A
- Revenue Next Year
- PTIX N/A
- QNRX N/A
- P/E Ratio
- PTIX N/A
- QNRX N/A
- Revenue Growth
- PTIX N/A
- QNRX N/A
- 52 Week Low
- PTIX $2.35
- QNRX $5.01
- 52 Week High
- PTIX $15.54
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- PTIX 53.21
- QNRX 64.78
- Support Level
- PTIX $3.55
- QNRX $8.04
- Resistance Level
- PTIX $3.97
- QNRX $8.58
- Average True Range (ATR)
- PTIX 0.23
- QNRX 0.46
- MACD
- PTIX 0.04
- QNRX 0.04
- Stochastic Oscillator
- PTIX 81.83
- QNRX 98.57
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.